| 发明名称 | Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage | ||
| 摘要 | The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise. | ||
| 申请公布号 | US9259408(B2) | 申请公布日期 | 2016.02.16 |
| 申请号 | US201313803038 | 申请日期 | 2013.03.14 |
| 申请人 | Brudy Technology S.L. | 发明人 | Domingo Pedrol Joan Carles;Villegas Garcia Jose Antonio |
| 分类号 | A01N37/06;A61K31/22;A01N37/02;A61K31/225;A01N37/00;A61K31/20;A61K31/202;A23L1/30;A61K47/12 | 主分类号 | A01N37/06 |
| 代理机构 | Baker & Hostetler LLP | 代理人 | Baker & Hostetler LLP |
| 主权项 | 1. A method of treating cellular oxidative damage comprising administering a foodstuff comprising docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or DHA-derived EPA to a subject affected by cellular oxidative damage associated with a neurodegenerative pathology, wherein said DHA, EPA, or DHA-derived EPA is enzymatically incorporated into a glyceride, a portion of said DHA, EPA, or DHA-derived EPA being incorporated into an sn-2 position of the glyceride. | ||
| 地址 | Barcelona ES | ||